Valion Bio Appoints Experienced General Counsel to Bolster Strategic Initiatives

summarizeSummary

Valion Bio, Inc. appointed Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs, a strategic hire with extensive biopharmaceutical and IP experience, crucial for the company's ongoing clinical development and capital raise efforts.

check_boxKey Events

• New General Counsel Appointed

  Melinda Lackey was appointed as General Counsel and Senior Vice President of Legal Affairs of Valion Bio, Inc., effective May 4, 2026.

• Extensive Biopharma and IP Experience

  Ms. Lackey brings over 18 years of legal and corporate experience, including executive and legal leadership roles at clinical-stage biotechnology companies and expertise in intellectual property strategy and public company governance.

• Significant Compensation Package

  Her compensation includes a $321,000 annual base salary and an option to purchase 45,000 shares of common stock, granted on May 1, 2026, with an exercise price equal to the fair market value on the grant date.

• Strategic Alignment with Company Goals

  Her appointment is highlighted as critical for advancing Entolimod™ through the FDA Animal Rule pathway, scaling Velocity Bioworks, and supporting capital raise initiatives, aligning with the company's recent rebranding and strategic shifts.

auto_awesomeAnalysis

This 8-K details a significant executive appointment for Valion Bio, Inc. Melinda Lackey's background in biopharmaceutical legal affairs, intellectual property, and public company governance is highly relevant given the company's current strategic initiatives, including the development of Entolimod, scaling its CDMO subsidiary, and ongoing capital raise efforts. The compensation package, including a substantial base salary and an option grant representing a notable percentage of the company's micro-cap valuation, reflects the importance of this hire. This appointment strengthens the company's leadership team at a critical juncture, following its recent rebranding and ahead of potential financing activities, as indicated by the DEF 14A filed on 2026-04-30 seeking approval for an expanded equity incentive plan.